Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Recurrence 8Lung Neoplasms 6Neoplasm Metastasis 5Lymphoma, T-Cell, Peripheral 4Breast Neoplasms 4Neoplasms 3Lymphoma, T-Cell 3Urinary Bladder Neoplasms 2Stomatitis 2Sezary Syndrome 2Papillomavirus Infections 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Meningeal Carcinomatosis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Anemia 2Waldenstrom Macroglobulinemia 1Vitamin B 12 Deficiency 1Ureteral Neoplasms 1Thyroid Diseases 1Thrombocytopenia 1Stroke 1Stomach Neoplasms 1Smoking 1Prostatic Neoplasms 1

Interventions

Brentuximab Vedotin 4Bexarotene 2iratumumab 1Vitamin B 12 1Salvia hispanica seed extract 1Methotrexate 1Lenalidomide 1Folic Acid 1Cholecalciferol 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Primary Cutaneous Anaplastic Large Cell × Vitamin B 12 × Clear all
NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡